Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 9/20 | 0.58 |
| ▸ | CRBN | Q96SW2 | 9/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.47 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.43 |
| ▸ | FPR3 | P25089 | 1/20 | 0.43 |
| ▸ | FPR2 | P25090 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30706234 | 0.91 | DDB1 (0.57) | DDB1CRBNGPR119 | |
| SCHEMBL30706186 | 0.89 | DDB1 (0.55) | DDB1CRBNFPR3FPR2 | |
| SCHEMBL30706246 | 0.89 | DDB1 (0.55) | DDB1CRBNFPR3FPR2 | |
| SCHEMBL31232829 | 0.89 | DDB1 (0.57) | DDB1CRBNKDM4EPKMGPR119 | |
| SCHEMBL30769278 | 0.85 | DDB1 (0.67) | DDB1CRBNGPR119PTPN2PTPN1 | |
| SCHEMBL26641333 | 0.84 | CRBN (0.60) | DDB1CRBNGPR119 | |
| SCHEMBL23301622 | 0.84 | CRBN (0.67) | DDB1CRBNKDM4EGPR119POLB | |
| SCHEMBL25187964 | 0.84 | CRBN (0.67) | DDB1CRBNKDM4EGPR119POLB | |
| SCHEMBL24206650 | 0.84 | CRBN (0.67) | DDB1CRBNKDM4EGPR119POLB | |
| SCHEMBL27040152 | 0.83 | CRBN (0.59) | DDB1CRBNGPR119POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709730-A1 | HETEROARYL COMPOUNDS AS LIGAND DIRECTED DEGRADERS OF IRAK4 | Celgene Corporation (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-4558495-A1 | HETEROARYL COMPOUNDS AS LIGAND DIRECTED DEGRADERS OF IRAK4 | Bristol-Myers Squibb Company (US) | 2025-05-28 | — | — | EP | disclosed |
| EP-4536649-A1 | QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | Treeline Biosciences, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| WO-2024233742-A1 | HETEROARYL COMPOUNDS AS LIGAND DIRECTED DEGRADERS OF IRAK4 | CELGENE CORPORATION (US) | 2024-11-14 | — | — | WO | disclosed |
| US-20240109881-A1 | Heteroaryl Compounds as Ligand Directed Degraders of IRAK4 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-04-04 | — | — | US | disclosed |
| WO-2024020084-A1 | HETEROARYL COMPOUNDS AS LIGAND DIRECTED DEGRADERS OF IRAK4 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-01-25 | — | — | WO | disclosed |
| WO-2024020084-A1 | HETEROARYL COMPOUNDS AS LIGAND DIRECTED DEGRADERS OF IRAK4 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-01-25 | — | — | WO | disclosed |
| WO-2023244918-A1 | QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | Treeline Biosciences, Inc. (US) | 2023-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240109881-A1 | Heteroaryl Compounds as Ligand Directed Degraders of IRAK4 | IRAK4, IRAK2, IRAK3 | DDB1 291/4885CRBN 184/4885KDM4E 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.